Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms COVID19 vaccine Laboratorios HIPRA, HIPRA SARSCoV2 vaccine, Recombinant protein RBD vaccine HIPRA + [5] |
Target |
Action inhibitors |
Mechanism SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (30 Mar 2023), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | European Union | 30 Mar 2023 | |
COVID-19 | Iceland | 30 Mar 2023 | |
COVID-19 | Liechtenstein | 30 Mar 2023 | |
COVID-19 | Norway | 30 Mar 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza, Human | Phase 2 | Spain | 04 Sep 2023 | |
SARS-CoV-2 acute respiratory disease | Phase 2 | Vietnam | 11 Nov 2021 |
Phase 2 | - | PHH-1V vaccine | eiulthpudu(ahuzcsxfas) = strong cellular immune response against the SARS-CoV-2 Wuhan-Hu-1 strain and the Beta, Delta, and Omicron BA.1 variants up to day 98 post-dosing jkrkdozkxv (vtiphdunyb ) View more | Positive | 01 Feb 2025 | ||
BNT162b2 vaccine |